Abstract
Chronic kidney disease (CKD) is characterized by a sustained pro-inflammatory response. The underlying mechanisms are incompletely understood, but may be linked to gut dysbiosis. Dysbiosis has been described in adults with CKD; however, comorbidities limit CKD-specific conclusions. We analyzed the fecal microbiome, metabolites and immune phenotypes in children at three different CKD stages (G3-G4, G5 (hemodialysis), after kidney transplantation) and healthy controls. Serum TNF-α and sCD14 were stage-dependently elevated, indicating inflammation and gut barrier dysfunction. We observed microbiome alterations in CKD, including a diminished production of short-chain fatty acids. Bacterial tryptophan metabolites were increased in CKD. CKD serum activated the aryl hydrocarbon receptor and stimulated TNF-α production by monocytes, corresponding to a shift towards intermediate/non-classical monocytes. Unsupervised T cell analysis revealed pro-inflammatory shifts in MAIT and Treg cells. Thus, gut barrier dysfunction and microbial metabolites exacerbate inflammation and may therefore contribute to the increased cardiovascular burden in CKD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by local resources of the participating institutions. JH was supported by the Peter-Stiftung fuer die Nierenwissenschaft. JH, MW, SKF, and UL were supported by the German Center for Cardiovascular Research (DZHK), partner site Berlin. UL was supported by the German Federal Ministry of Education and Research (EMBARK; 01KI1909B) under the frame of JPI AMR (EMBARK; JPIAMR2019-109). S.G. was supported by the Bundesministerium fuer Bildung und Forschung funding MSTARS (Multimodal Clinical Mass Spectrometry to Target Treatment Resistance). F.B. was supported by the Berlin Institute of Health BIH-MD-TRENAL stipend. NW was supported by the European Research Council (ERC) under the European Unions Horizon 2020 research and innovation program (852796) and by a grant from the Corona-Stiftung in the German Stifterverband. NW and SKF were supported by the Deutsche Forschungsgemeinschaft (German Research Foundation, SFB 1365 and SFB 1470). The sponsors had no involvement in study design, data collection, analysis and interpretation of data and in the decision to submit this article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Charite-Universitaetsmedizin Berlin gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors